Phase 2 N=55 Antiplatelet Therapy in HIV
HIV · Cardiovascular Diseases · Inflammation
Primary: Percentage Platelet Aggregation in PRP After Stimulation With Arachidonic Acid 1600 μM for 5 Min — 72.35; 79.11; 72.79; 26.77 %aggregation
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=48 Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin Study
Chronic Kidney Disease
Primary: Whole Blood Platelet Aggregation to 0.5 Millimoles Arachidonic Acid — 21.0; 18.0; 0; 0 ohms
Phase 4 N=60 Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction
Myocardial Infarction
Primary: Concentration of Platelet Extracellular Vesicles/ml — 2690000; 4310000 Platelet Extracellular Vesicles/mL
N/A N=184 Platelet Inhibition and Bleeding in Patients Undergoing Emergent Cardiac Surgery
Bleeding
Primary: Calculated Blood Loss — 1996 milliters
Phase 4 N=30 Platelet Inhibition in Patients With Systolic Heart Failure
Systolic Heart Failure
Primary: The Change in Platelet Aggregation Measured by the Accumetrics (VerifyNow P2Y12) Assay Between Baseline and Each Antiplatelet Medication — 66.4; 156.2 PRU (P2Y12…
Phase 4 N=24 Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation
Coronary Artery Disease
Primary: Change From Baseline in ADP-mediated Platelet Aggregation, APP, SFFLRN, AYPGKF. — 84; 38; 94; 53 % inhibitn of platelet aggregation — p=0.001
N/A N=99 Platelet Function in Resuscitated Patients
Acute ST Segment Elevation Myocardial Infarction
Primary: Platelet Inhibition Measured With Optical Aggregometry — 109; 253.8 AU*min
Phase 2 N=98 A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders
Stable Coronary Artery Disease
Primary: Proportion of Clopidogrel Non-responders Who Responded to Clopidogrel or Ticagrelor. - Comparing Ticag. (Day 28 of Clop. to Ticag., and Day 14 of Ticag. to Clop.) Versus…
N/A N=20 Effects of Incretins on Human Platelet Function
Inhibition of Platelet Aggregation by Incretins
Primary: Expression of Glucagon Like Peptide -1 (GLP-1) and Gastric Inhibitory Peptide (GIP) Receptors in Normal Human Platelets — 3.73; 4.42 percentage of positive cells — p=0.04
N/A N=60 In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients
Coronary Artery Disease
Primary: Platelet Reactivity Index (PRI) Determined by Whole Blood Vasodilator-stimulated Phosphoprotein (VASP) — 30; 30; 18; 17 %PRI
Phase 2 N=123 A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin
Coronary Artery Disease
Primary: Final Extent Inhibition of Platelet Aggregation (IPA) Induced by 20 µM Adenosine Diphosphate (ADP) at 2 Hours After First Dose — 93.15; 31.05 Percentage
Phase 2 N=27 Targeting Platelets in Chronic HIV Infection
HIV-1 Infection
Primary: Change in sCD14 From Baseline to Week 24 — 35.75; -251.40; -101.75 pg/mL
Phase 2 N=40 Effects of Pioglitazone on Platelet Function
Diabetes · Platelet Function · Healthy
Primary: Percent Platelet Aggregation Induced by Arachidonic Acid — 80; 90; 60; 29 maximum percentage aggregation
Phase 4 N=87 P3AMI Antiplatelet Trial
Heart Attack
Primary: Pharmacodynamic Assessment of Degree of Platelet Inhibition as Determined by Verify Now Point of Care Assay and Expressed as P2Y12 Reaction Units (PRU) — 270.23; 247.73…
N/A N=117 Genetic Variation in Platelet Aggregation
Myocardial Infarction
Primary: LogEC50 Platelet Aggregation — 2.65; 2.62 nM
Phase 4 N=212 The Platelet Aggregation After tiCagrelor Inhibition and FentanYl Trial (PACIFY)
Coronary Artery Disease
Primary: Ticagrelor Pharmacokinetics — 3301; 2107 ng*hr/mL
Phase 4 N=81 Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI
Coronary Artery Disease
Primary: Platelet Reactivity Measured as PRU — 154.5; 23; 104 PRU
N/A N=334 Platelet Reactivity (High On-Treatment Platelet Reactivity) as Guidance for APT (Antiplatelet Therapy) Adjustment After PCI (Percutaneous Coronary Intervention)
PRU(Platelet Reactivity Unit) · APT(Antiplatelet Therapy) · HOTPR(High on Treat Platelet Reactivity)
Primary: Numbers of Participants With MACE(Major Adverse Cardiac Event) of Study Subjects — 1; 1; 2 numbers of participants with MACE — p=0.002
Phase 4 N=302 Clopidogrel and Aspirin Interaction Study-2
Drug Action Increased
Primary: Blood Concentration of the Active Metabolite of Clopidogrel — 14.45; 13.80 ng/ml — p=0.66
N/A N=60 Impact of Ticagrelor Re-load on Pharmacodynamic Profiles
Coronary Artery Disease
Primary: Platelet Reactivity Index (PRI) by Vasodilator-stimulated Phosphoprotein (VASP) — 17.87; 23.4 PRI%
N/A N=16 PACT (Platelet Activity After Clopidogrel Termination)
Blood Platelets · Clopidogrel
Primary: Change From Baseline in Platelet Surface Activated GPIIb-IIIa Complex at 45 Days After Intervention. — 123.2; 126.7 mean fluorescence intensity (MFI)
Phase 3 N=93 Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events
Stroke · Myocardial Infarctions
Primary: PFA1 — 202.0; 271.1; 234.7 seconds — p=0.0742
Phase 2 N=36 Aspirin Resistance and Percutaneous Coronary Intervention (PCI)
Stable Angina
Primary: Number of Participants With Elevation of Cardiac Enzyme — 4; 2 Participants
Phase 4 N=5,276 Tailored Antiplatelet Therapy Following PCI
Coronary Artery Disease · Acute Coronary Syndrome · Stenosis
Primary: Occurrence of the a Major Adverse Cardiovascular Event in Subjects Identified as CPY2C19 LOF Carriers by TaqMan. — 35; 54 Participants
N/A N=82 Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor
Coronary Artery Disease · Acute Coronary Syndrome
Primary: Platelet Reactivity Measured as P2Y12 Reaction Units (PRU) Determined by Verify Now-P2Y12 Assay — 45; 63 PRU
Phase 2 N=15 Anti-Platelets in Chronic Obstructive Pulmonary Disease
COPD · Emphysema · Emphysema or COPD
Primary: Pulmonary Microvascular Blood Volume, CV — 0.89; 0.88; 0.92; 0.91 CV — p=0.84
Phase 2 N=70 Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion
Acute Coronary Syndrome
Primary: Change in Percent Inhibition of Platelet Aggregation (%IPA) — 99.59; 99.88 percentage of IPA
N/A N=246 Platelet Activity in Vascular Surgery and Cardiovascular Events
Cardiovascular Disease · Peripheral Artery Disease · Critical Limb Ischemia
Primary: Number of Patients in Which Platelet Activity Measurements Were Associated With Short-term Cardiovascular Events — 31; 16 participants
Phase 2 N=282 Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients
Acute Coronary Syndrome
Primary: Adenosine Diphosphate (ADP)-Induced P2Y12 Receptor-Mediated Platelet Aggregation 6 Hours After Prasugrel Loading Dose (LD) — 57.86; 35.61; 53.92 PRU — p=0.188
Phase 3 N=18,624 A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome
Acute Coronary Syndrome
Primary: Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke — 864; 1014 Participants